Abstract B8: Predictors of <i>BRCA1/2</i> genetic testing in a population of newly diagnosed breast cancer patients
Rachel Nusbaum(Icahn School of Medicine at Mount Sinai), Marc A. Schwartz(University of Washington), Kara‐Grace Leventhal(University of Maryland, Baltimore), Lina Jandorf(Icahn School of Medicine at Mount Sinai), Costanza Cocilovo(Icahn School of Medicine at Mount Sinai), Patti Vegella(Georgetown University), Rebecca S. Evangelista(Icahn School of Medicine at Mount Sinai), Sarah A. Kelleher(Icahn School of Medicine at Mount Sinai), Scott P. Kelly(Pfizer (United States)), Jessica Rowse(Icahn School of Medicine at Mount Sinai), Claudine Isaacs(Georgetown University), Colette Magnant, Heiðdís Valdimarsdóttir(Reykjavík University), Shawna C. Willey(Georgetown University), Beth N. Peshkin(Georgetown University), Elizabeth Carroll(Georgetown University), Andrea Forman(Fox Chase Cancer Center)
Cited by 0
Related Papers
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy
|New England Journal of Medicine|2012|1k
Elastography of breast lesions: initial clinical results.
|Radiology|1997|934
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Screening by Chest Radiograph and Lung Cancer Mortality
|JAMA|2011|659